

Remarks

Claims 1-73 are pending in the application. The Group I claims have been elected without traverse with the reservation that the Group VI and VII claims may be rejoined in accordance with the provisions of MPEP §821.04.

Claim 1 has been amended to correspond to the restriction requirement by incorporating the limitations of Claims 5, 6, 32 and 33 into Claim 1 (i.e., A is nitrogen, B is carbon and X is a bond). Consequently, Claims 5, 6, 32 and 33 have been cancelled. Similarly, Claims 44, 46, 50 and 52 have been incorporated into Claim 42 in response to the restriction requirement.

Claims 12-29, 37-41, 45, 47, 48, 51, 53, 54 and 56-58 have been cancelled as being directed to non-elected subject matter. Claims 59-73 currently stand withdrawn by the Examiner and subject to rejoinder.

Claims 7, 10 and 34 have been amended to provide proper dependency of claims.

Respectfully Submitted:

Date: _____

June 27, 2005

Arlene K. Musser

Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871